Surmodics goes head-to-head with Medtronic ’ s drug-coated balloon in pivotal trial

Surmodics (NSDQ:SRDX) announced today that the first patient was enrolled in a pivotal clinical trial evaluating its SurVeil drug-coated balloon.
The 446-patient trial is designed to compare the company’s SurVeil device to Medtronic‘s (NYSE:MDT) In.Pact Admiral drug-coated balloon as a treatment for peripheral artery disease in the upper leg.
Get the full story at our sister site, Drug Delivery Business News.
The post Surmodics goes head-to-head with Medtronic’s drug-coated balloon in pivotal trial appeared first on MassDevice.

Source: Mass Device - October 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Vascular Wall Street Beat Medtronic SurModics Inc. Source Type: news